Pfizer Inc. (NYSE:PFE) Given Average Rating of “Hold” by Brokerages

Pfizer Inc. (NYSE:PFEGet Free Report) has been given an average rating of “Hold” by the seventeen analysts that are presently covering the firm, Marketbeat.com reports. Eleven research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $36.88.

PFE has been the subject of several recent analyst reports. Truist Financial decreased their price objective on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. UBS Group reduced their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. Finally, TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th.

Get Our Latest Report on PFE

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Fulton Bank N.A. lifted its holdings in shares of Pfizer by 4.7% in the third quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company’s stock valued at $5,846,000 after purchasing an additional 7,991 shares in the last quarter. Portside Wealth Group LLC acquired a new stake in Pfizer during the second quarter worth approximately $2,072,000. Adage Capital Partners GP L.L.C. boosted its position in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the last quarter. Brookstone Capital Management boosted its position in Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after acquiring an additional 212,369 shares during the last quarter. Finally, ETF Store Inc. boosted its position in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.6 %

Shares of NYSE PFE opened at $27.55 on Wednesday. Pfizer has a 1 year low of $25.61 and a 1 year high of $42.22. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a 50 day simple moving average of $27.43 and a 200-day simple moving average of $29.29. The company has a market capitalization of $156.00 billion, a P/E ratio of 76.53, a P/E/G ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.14 earnings per share. On average, equities research analysts predict that Pfizer will post 2.22 earnings per share for the current year.

About Pfizer

(Get Free Report

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.